Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Down 12.22%
As of Thursday, June 25, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 12.22%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. AQST
$3.70
-0.03
-0.67%
July 31, 2026 4:00:00 PM
EST
Volume: 1,785,632
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Commentary & Analysis
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Down 15.53%
As of Thursday, June 25, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 15.53%, which has investors questioning if this is right time to buy.Omar Beirat
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Up 5.56%
As of Tuesday, June 23, Aquestive Therapeutics, Inc.’s AQST share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Up 5.42%
As of Thursday, June 18, Aquestive Therapeutics, Inc.’s AQST share price has surged by 5.42%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Aquestive Therapeutics, Inc.’s (AQST) Stock Is Down 6.98%
As of Friday, May 15, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 6.98%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | AQST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $466.7 | $569.9 | 37% |
|
| Shares Out (Mil) | 122.6 | 44.8 | 67% |
|
| Institutional Ownership | 95.0% | 84.6% | 66% |
|
| Float (Mil) | 114.6 | 45.1 | 64% |
|
| Beta | 1.50 | 0.67 | 82% |
|
| Avg Daily Volume (000s) | 2,084 | 294 | 83% |
|
| Price Change (52-week) |
(5.3%) | 65.2% | 41% |
|
| Growth | AQST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.6%) | 6.7% | 16% |
|
| Net Income (5yr) | (8.5%) | (2.0%) | 30% |
|
| EPS (5yr) | 13.9% | 14.9% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 23.6% | (14.9%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 1 | |
| Current EPS | ($0.120) | ($0.420) | ($0.450) | |
| Month Ago EPS | ($0.120) | ($0.420) | ($0.450) | |
| # Rev Up | 1 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.115) | ($0.460) | ($0.580) | |
| Year/Year Chg | 81.8% | (46.4%) | (80.9%) | |
| Financials | AQST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $50 | $230 | 20% |
|
| Net Income (TTM) (Mil) | ($69) | ($11) | 14% |
|
| EPS (TTM) | ($0.606) | ($0.600) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($44) | ($6) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $42 | $4 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $29 | $7 | 35% |
|
| Enterprise Value (Q1) (Mil) | $526 | $493 | 35% |
|
| Valuation | AQST | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.89 | na |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AQST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.5% | 65.9% | 76% |
|
| Net Margin | (137.1%) | (0.2%) | 6% |
|
| ROA | (56.6%) | (25.5%) | 11% |
|
| ROE | 145.1% | (21.4%) | 97% |
|
| Liabilities to Assets | 124.1% | 35.5% | 97% |
|
| F-Score | 2 | 3 | 7% |
|
Aquestive Therapeutics, Inc. did not pass any screens on 7/30/2026.
